Stockreport
Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand [Seeking Alpha]
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth. Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF. Guidance for 2026 targets $12.95–$13.1 billion in total revenue, with non-CF products expected to contribute over $500 million. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Olga Yastremska/iStock via Getty Images The last time I spoke about Vertex Pharmaceuticals VRTX ) it was with a Seeking Alpha article entitled " Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy ." With respect to this article, I mentioned that the More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | VRTX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
VRTX alerts
VRTX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
NEWS
NEWS
- Vertex to Announce First Quarter 2026 Financial Results on May 4th[Business Wire]
- Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance][Yahoo! Finance]
- Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision [Yahoo! Finance][Yahoo! Finance]
- Vertex Pharma wins FDA label expansion for cystic fibrosis therapies [Seeking Alpha][Seeking Alpha]
- Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States [Yahoo! Finance][Yahoo! Finance]
- More
VRTX
SEC Filings
SEC Filings
- 4/3/26 - Form 4
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- VRTX's page on the SEC website
- More